# Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

> **NCT01154101** · PHASE2 · COMPLETED · sponsor: **Sirtris, a GSK Company** · enrollment: 40 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Placebo
- **DRUG:** SRT2104

## Key facts

- **NCT ID:** NCT01154101
- **Lead sponsor:** Sirtris, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-07
- **Primary completion:** 2011-11-09
- **Final completion:** 2011-11-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154101, "Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01154101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*